Literature DB >> 19585472

Efficacy of purslane in the treatment of oral lichen planus.

Farzaneh Agha-Hosseini1, Katayun Borhan-Mojabi, Hamid-Reza Monsef-Esfahani, Iraj Mirzaii-Dizgah, Shahroo Etemad-Moghadam, Aida Karagah.   

Abstract

This study evaluated the effectiveness of antioxidant-rich purslane in the treatment of oral lichen planus (OLP). A total of 37 biopsy-proven symptomatic OLP patients were selected for this randomized double-blind placebo-controlled trial. All subjects were divided into two groups to receive purslane (n = 20) or placebo (n = 17) for 3 months. Assessments were made at baseline, after 2 weeks and each month for 6 months, based on the visual analog scale (VAS) and clinical improvement including lesion type and size. Approximately 83% of the purslane patients showed partial to complete clinical improvement but 17% had no response. In the placebo group 17% experienced partial improvement, 73% did not respond and 10% showed worsening. According to VAS scores, a partial to complete response was observed in all purslane-treated patients, while 71%, 15% and 14% of the controls demonstrated partial response, no response and worsening of the symptoms, respectively. A significant decrease in VAS scores was seen at the end of the study period (p < 0.001). No serious side-effects occurred in either of the groups. According to our findings purslane is clinically effective in the treatment of OLP. Considering the lack of side-effects during the study period, it may be a favorable alternative treatment for OLP. (c) 2009 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19585472     DOI: 10.1002/ptr.2919

Source DB:  PubMed          Journal:  Phytother Res        ISSN: 0951-418X            Impact factor:   5.878


  9 in total

1.  Interventions for treating oral lichen planus: corticosteroid therapies.

Authors:  Giovanni Lodi; Maddalena Manfredi; Valeria Mercadante; Ruth Murphy; Marco Carrozzo
Journal:  Cochrane Database Syst Rev       Date:  2020-02-28

2.  Serum and saliva collagenase-3 (MMP-13) in patients with oral lichen planus and oral squamous cell carcinoma.

Authors:  Farzaneh Agha-Hosseini; Iraj Mirzaii-Dizgah
Journal:  Med J Islam Repub Iran       Date:  2015-06-07

3.  Evaluation of Plasma Isoprostane in Patients with Oral Lichen Planus.

Authors:  Maryam Amirchaghmaghi; Seyed Isaac Hashemy; Banafsheh Alirezaei; Fereshteh Jahed Keyhani; Sanaz Kargozar; Samaneh Vasigh; Shideh Gharaei; Atessa Pakfetrat
Journal:  J Dent (Shiraz)       Date:  2016-03

4.  Salivary MMP-1, MMP-2, MMP-3 and MMP-13 Levels in Patients with Oral Lichen Planus and Squamous Cell Carcinoma

Authors:  Tahereh Nosratzehi; Ebrahim Alijani; Marziyeh Moodi
Journal:  Asian Pac J Cancer Prev       Date:  2017-07-27

5.  Salivary β2-microglobulin levels in patients with erosive oral lichen planus and squamous cell carcinoma.

Authors:  Fatemeh Nosratzehi; Tahereh Nosratzehi; Ebrahim Alijani; Soha Saberi Rad
Journal:  BMC Res Notes       Date:  2020-06-17

Review 6.  Therapeutic effectiveness of alternative medications in oral lichen planus: A systematic review.

Authors:  Jayanth Kumar Vadivel; Devaraj Ezhilarasan; Meera Govindarajan; Elangovan Somasundaram
Journal:  J Oral Maxillofac Pathol       Date:  2020-09-09

Review 7.  A review on bioactive phytochemicals and ethnopharmacological potential of purslane (Portulaca oleracea L.).

Authors:  Ajay Kumar; Sajana Sreedharan; Arun Kumar Kashyap; Pardeep Singh; Nirala Ramchiary
Journal:  Heliyon       Date:  2021-12-27

8.  Diets containing traditional and novel green leafy vegetables improve liver fatty acid profiles of spontaneously hypertensive rats.

Authors:  Melissa Johnson; Ralphenia D Pace; Norma L Dawkins; Kyle R Willian
Journal:  Lipids Health Dis       Date:  2013-11-05       Impact factor: 3.876

Review 9.  Short Overview of Some Assays for the Measurement of Antioxidant Activity of Natural Products and Their Relevance in Dermatology.

Authors:  Morana Jaganjac; Vesna Sredoja Tisma; Neven Zarkovic
Journal:  Molecules       Date:  2021-08-31       Impact factor: 4.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.